Browse the corpus

Cogan syndrome is a rare multisystem vasculitis of unknown pathogenesis that primarily affects the ocular and audiovestibular systems. The condition most often occurs in young White adults during the second to third decades of life and demonstrates equal incidence between sexes. Hallmark clinical features include interstitial keratitis and sensorineural hearing loss, frequently accompanied by vestibular symptoms. Although the precise pathophysiology remains incompletely understood, current evidence supports an autoimmune mechanism, and the disease is classified as a variable vessel vasculitis. Diagnosis is one of exclusion and depends on recognition of characteristic ocular and audiovestibular findings after infectious causes have been ruled out. Disease progression may lead to irreversible complications, including deafness, vision loss, and systemic manifestations such as aortitis and other vasculitic sequelae. Management is individualized because of disease rarity and heterogeneity, with systemic corticosteroids as first-line therapy and immunomodulatory or biologic agents reserved for refractory cases. This educational activity enhances clinician competence in recognizing the early manifestations of Cogan syndrome and differentiating it from other inflammatory and infectious conditions with overlapping features. Participants refine diagnostic strategies, gain insight into proposed etiologies and clinical variability, and review evidence-based approaches to immunosuppressive management. Emphasis is placed on identifying gaps in care, including delayed diagnosis, inconsistent steroid tapering, and underrecognition of systemic vascular involvement. Collaboration within an interprofessional healthcare team, including ophthalmology, otolaryngology, rheumatology, and cardiology, supports comprehensive evaluation, coordinated treatment planning, and ongoing monitoring, thereby improving visual, auditory, and systemic outcomes. Objectives: Identify early signs of relapse, treatment resistance, or systemic involvement to prevent permanent hearing loss, vision impairment, or vascular complications for patients with Cogan syndrome. Determine the pathophysiology, histopathology, clinical features, differential diagnoses, prognosis, and complications of Cogan syndrome.

Identify early signs of relapse, treatment resistance, or systemic involvement to prevent permanent hearing loss, vision impairment, or vascular complications for patients with Cogan syndrome. Determine the pathophysiology, histopathology, clinical features, differential diagnoses, prognosis, and complications of Cogan syndrome. Develop longitudinal monitoring strategies to track disease activity, treatment response, medication toxicity, and progression of vascular complications. Collaborate and communicate effectively within the interprofessional healthcare team, including ophthalmology, otolaryngology, rheumatology, cardiology, and primary care, to coordinate comprehensive care and optimize patient outcomes. Access free multiple choice questions on this topic.

Cogan syndrome is a rare systemic vasculitis characterized by inflammation of the inner ear and eyes.[1] Baumgartner and Morgan first described the condition in 1934 as non–syphilitic interstitial keratitis associated with vestibular dysfunction in a patient with Ménière disease.[2] Dr David G. Cogan later defined it as a distinct clinical entity in 1947.[3] The diagnosis of Cogan syndrome is one of exclusion. This condition typically affects young adults in their second or third decade of life.[4] The proposed pathogenesis involves autoantibodies directed against antigens in the cornea, inner ear, and vascular endothelium.[5] Cogan syndrome is classified into typical and atypical forms. Typical Cogan syndrome is defined by the onset of ophthalmologic and audiovestibular symptoms within 2 years of each other, usually within 3 to 90 days.[1][6] Atypical Cogan syndrome is diagnosed when this interval exceeds 2 years.[1] Systemic manifestations may include fever, arthralgias, myalgias, arthritis, headache, and aortitis. Cogan syndrome is generally managed with corticosteroids to reduce the frequency and severity of flares and prevent irreversible complications such as sensorineural hearing loss, vestibular dysfunction, blindness, and cardiovascular involvement. Progressive or refractory cases may require biologic or immunomodulatory therapy, and severe cases may need surgical intervention.[1][7][8]

Cogan syndrome was initially thought to have an infectious origin, particularly related to Chlamydia psittaci, based on reports of elevated antibody titers to Chlamydia trachomatis and exposure history in a few patients.[9] However, results from subsequent studies, including those by Vollertsen et al, failed to confirm a causal link.[10] Further investigations have not identified a consistent infectious agent, and antibiotic therapy has been ineffective.[3] Attention has since shifted to an autoimmune etiology. Patients have demonstrated elevated levels of immunoglobulin G (IgG) and A (IgA) antibodies against human corneal tissue, as well as IgG4 antibodies targeting inner ear tissue.[11] The pathogenic role of these antibodies has been explored using pooled IgG from patients with Cogan syndrome, which reacted with autoantigenic peptides homologous to proteins expressed in the sensory epithelia of the inner ear and in endothelial cells.[5] Passive transfer of these antibodies to mice reproduced features consistent with Cogan syndrome, supporting an autoimmune mechanism.[5] Infectious or inflammatory triggers may contribute to the initiation of this autoimmune response. Cogan syndrome follows an upper respiratory tract infection episode in 32% to 65% of reported cases.[12] A history of diarrhea, immunization, or dental infection may also precede disease onset.[3][13] Since the onset of the COVID-19 pandemic, 2 cases of atypical Cogan syndrome have been reported following SARS-CoV-2 infection.[12] Additionally, infection may not be the only trigger. In a recent case series, hemostatic chitosan-tamponade was proposed as a potential trigger after three cases of Cogan syndrome occurred following its use for postpartum hemorrhage.[14] Although causality remains unproven, this association underscores the possible role of immune activation following mucosal or vascular injury. Efforts to identify a specific serological marker for Cogan syndrome have focused on anti-Hsp70 antibodies, which have been detected in some patients with typical Cogan syndrome; however, the finding is inconsistent, particularly in atypical forms.[15] At this time, no single antibody has been established as a definitive diagnostic marker.[3][16]

Cogan syndrome is a rare disorder, with an estimated prevalence of less than 1 in 500,000 people and approximately 250 cases reported worldwide since its initial description in 1945.[6] The true incidence may be underestimated due to misdiagnosis or incomplete recognition of atypical forms.[3][17][18] In the United States, approximately 60 cases have been documented over the past 62 years.[19] The disease predominantly affects White adults, typically presenting in the second to third decade of life, with a mean age of onset of 25 years (range: 5–63 years).[1][20][21] Although less common in the pediatric population, 55 childhood cases have been reported, with a median age at diagnosis of 12 years.[22] There is no clear sex or racial predominance among reported cases.[1][23]

Cogan syndrome is believed to be an autoimmune disorder that targets ocular, inner-ear, and vascular tissues.[5] Histopathologic studies demonstrate lymphocytic and plasma cell infiltration, vascular inflammation, and fibroblast proliferation, consistent with a chronic inflammatory process.[24][25] Further research has investigated the autoimmune hypothesis by analyzing serum samples from patients with Cogan syndrome compared with healthy controls. Elevated levels of IgG and A antibodies against human corneal tissue, as well as IgG antibodies targeting inner ear tissue, have consistently been identified in patients with Cogan syndrome.[11] Results from functional studies have also demonstrated that these IgG antibodies react with autoantigen peptides homologous to proteins expressed in the sensory epithelia of the inner ear and on vascular endothelial cells.[5] In experimental models, passive transfer of patient IgG to mice induced clinical features resembling Cogan syndrome, including cochlear inflammation, vestibular dysfunction, and interstitial keratitis, providing strong evidence that these autoantibodies are pathogenic in disease development.[5] In the inner ear, antibody-mediated immune responses appear to damage the organ of Corti, spiral ganglion cells, and cochlear neurons, resulting in sensorineural hearing loss, tinnitus, and vestibular symptoms, including vertigo and imbalance.[25][26][27] In ocular tissues, autoimmune mechanisms target corneal stromal cells and endothelium, resulting in mononuclear cell infiltration, corneal neovascularization, and stromal inflammation, which manifest clinically as interstitial keratitis, photophobia, blurred vision, and potential vision loss.[1][8] These immune-mediated processes are more pronounced in typical Cogan syndrome but may also contribute to the ocular involvement seen in atypical Cogan syndrome.

In the inner ear, antibody-mediated immune responses appear to damage the organ of Corti, spiral ganglion cells, and cochlear neurons, resulting in sensorineural hearing loss, tinnitus, and vestibular symptoms, including vertigo and imbalance.[25][26][27] In ocular tissues, autoimmune mechanisms target corneal stromal cells and endothelium, resulting in mononuclear cell infiltration, corneal neovascularization, and stromal inflammation, which manifest clinically as interstitial keratitis, photophobia, blurred vision, and potential vision loss.[1][8] These immune-mediated processes are more pronounced in typical Cogan syndrome but may also contribute to the ocular involvement seen in atypical Cogan syndrome. Cogan syndrome is a multiorgan autoimmune disorder that is not limited to ocular or audiovestibular structures.[1] Systemically, autoantibodies may bind to endothelial antigens in medium- and large-sized vessels and cause vascular inflammation, which can result in diffuse vasculitis, aortitis, aneurysm formation, arterial stenosis, and secondary cardiovascular complications.[28][29] Additional systemic symptoms, such as arthralgias, myalgias, and fever, may reflect the presence of circulating immune complexes and endothelial activation in smaller vessels.[22] Together, these studies support a central pathogenic role for autoantibodies in Cogan syndrome, linking molecular immune mechanisms to the clinical triad of inner ear, ocular, and systemic involvement.

Histopathologic examination in Cogan syndrome reveals a chronic inflammatory process affecting multiple tissues, consistent with an autoimmune etiology.[24][25] In the cochlea, there is lymphoplasmacytic infiltration, degeneration of the organ of Corti, loss of spiral ganglion cells, and atrophy of cochlear neurons. Endolymphatic hydrops and secondary bone formation may occur, contributing to progressive sensorineural hearing loss and vestibular dysfunction.[25][26] The vestibulocochlear nerve may exhibit demyelination and atrophy, which correlates clinically with the symptoms of vertigo, imbalance, and tinnitus.[25] Ocular histopathology predominantly involves the corneal stroma, showing mononuclear cell infiltration, plasma cells, and stromal edema.[1][24] Corneal neovascularization is common, particularly in the posterior stroma near the limbus, and may lead to stromal scarring and vision loss.[1] In atypical Cogan syndrome, inflammation may extend to the iris, ciliary body, retina, or optic nerve, producing uveitis, scleritis, choroiditis, papillitis, or retinal vasculitis.[8][30] Systemic involvement includes vasculitis of medium- and large-sized vessels.[28][29] Histopathologic examination of affected vessels and valves shows lymphoid cell infiltration, myxomatous changes, fibrinoid necrosis, and intimal thickening.[31][32][33][34][35] In the aorta, these inflammatory changes may result in valvular insufficiency, aneurysm formation, and arterial wall weakening, giving rise to the cardiovascular complications that are the leading cause of mortality in Cogan syndrome.[28] Other organs, including the kidneys and brain, may show evidence of immune-mediated ischemia or infarction, consistent with systemic vasculitis.[36]

The initial presentation of a patient with Cogan syndrome commonly involves either ophthalmologic symptoms (41%) or audiovestibular symptoms (43%), with the latter often mimicking Ménière disease, including vertigo, nausea, vomiting, aural fullness, and tinnitus.[19][27] Ophthalmological symptoms in typical Cogan syndrome present primarily as iritis and non-syphilitic interstitial keratitis (see Image. Interstitial Keratitis, Slit Lamp). In contrast, atypical Cogan syndrome may involve retinal vasculitis, papillitis, central retinal artery occlusion, scleritis, or episcleritis.[8] Around 74% of patients with Cogan syndrome experience eye pain and redness; 50% experience photophobia, tearing, and ocular discomfort; and 42% experience blurred vision.[1] Cogan syndrome follows an upper respiratory tract infection episode in 32% to 65% of reported cases.[12] Patients may also report a history of diarrhea, immunizations, or dental infections. A recent case series identified hemostatic tamponade using chitosan-based materials as a possible iatrogenic trigger, with three cases of Cogan syndrome developing after patients underwent chitosan tamponade for postpartum hemorrhage.[14] Physical examination in a patient presenting with Cogan syndrome may reveal spontaneous nystagmus, ataxia, and progressive unilateral or bilateral sensorineural hearing loss (SNHL), which can develop over hours to days and may ultimately progress to total hearing loss. Audiometric evaluation typically demonstrates SNHL across all frequencies, and word recognition ability may vary; electronystagmography often reveals vestibular dysfunction.[37] Ophthalmic examination may reveal ciliary injection, stromal opacities, granular corneal infiltration, and secondary corneal neovascularization, usually affecting both eyes but with possible asymmetry.[30] As previously stated, Cogan syndrome is subdivided into typical and atypical forms (see Table. Comparison Between Typical and Atypical Cogan Syndrome). Typical Cogan syndrome is defined by the development of ophthalmologic and audiovestibular symptoms within two years of each other, with an average interval of 3 to 90 days. Atypical Cogan syndrome is diagnosed when there is a delay of more than two years between the onset of these symptoms.[1] Table. Comparison Between Typical and Atypical Cogan Syndrome Table

As previously stated, Cogan syndrome is subdivided into typical and atypical forms (see Table. Comparison Between Typical and Atypical Cogan Syndrome). Typical Cogan syndrome is defined by the development of ophthalmologic and audiovestibular symptoms within two years of each other, with an average interval of 3 to 90 days. Atypical Cogan syndrome is diagnosed when there is a delay of more than two years between the onset of these symptoms.[1] Table. Comparison Between Typical and Atypical Cogan Syndrome Table Systemic manifestations of Cogan syndrome occur in 30% to 80% of patients and may include fever, weight loss, fatigue, arthralgias, myalgias, and erythromelalgia.[22] Cardiovascular involvement, present in approximately 10% of patients, represents the leading cause of mortality in Cogan syndrome and may manifest as large-vessel vasculitis, aortitis, aortic aneurysm or dissection, aortic valve perforation, and, less commonly, coronary artery involvement leading to myocardial infarction.[28] Neurological symptoms occur in up to 33% of patients; they may include headache, hemiparesis, hemiplegia, aphasia, cerebellar syndrome, epilepsy, meningeal syndrome, or encephalitis secondary to inflammatory effects on medium and large vessels.[1][22] Gastrointestinal (GI) manifestations, including abdominal pain, hepatitis, and GI hemorrhage, have been reported in up to 22%, 11%, and 16.6% of cases, respectively.[21] Musculoskeletal involvement may include arthritis, myalgias, synovitis, arthralgias, and articular effusion, with muscle biopsies sometimes showing atrophy or necrosis that can mimic myositis.[38] Less common systemic findings include cutaneous lesions (urticarial rash, erythematous nodules, ulcerations, vascular purpura), pulmonary involvement (dyspnea, cough, pleurisy, hemoptysis, thoracic pain, radiographic abnormalities), urinalysis abnormalities, and lymphadenopathy.[1][38] Additional organs, such as the liver, spleen, kidneys, and urogenital tract, may also be affected. Hepatic involvement may manifest as hepatitis or mild transaminase elevation, while splenic changes can include splenomegaly or reactive lymphoid hyperplasia. Renal involvement may present as proteinuria, hematuria, or glomerulonephritis.[1]

Cogan syndrome remains a diagnosis of exclusion, as there is no definitive biomarker, radiologic finding, or histologic feature that is pathognomonic for the disease.[1] Audiologic evaluation is critical and typically includes pure-tone audiometry, which characteristically reveals SNHL across multiple frequencies, and word recognition testing, which may fluctuate over time. Electronystagmography or videonystagmography can demonstrate vestibular dysfunction, often correlating with clinical vertigo and imbalance.[37] Ophthalmologic evaluation should assess for interstitial keratitis, iritis, uveitis, scleritis, retinal vasculitis, or papillitis, depending on whether the patient has typical or atypical Cogan syndrome. Slit-lamp examination, fundoscopy, and fluorescein angiography can help characterize the extent of ocular involvement. Laboratory evaluation may reveal nonspecific inflammatory changes, including anemia, leukocytosis, thrombocytosis, elevated erythrocyte sedimentation rate, and elevated C-reactive protein during active disease flares. Hypofibrinogenemia may also be observed in acute episodes. Although antibodies against Chlamydia trachomatis or Chlamydia psittaci may occasionally be detected, such findings are inconsistent and non-diagnostic.[30] Renal involvement can be evaluated with urinalysis, which may reveal proteinuria or hematuria and, in some cases, immune-mediated glomerular injury. Additional serologic testing may include antinuclear antibodies, antibodies to smooth muscle, lupus anticoagulants, cryoglobulins, anti-neutrophil cytoplasmic antibodies, or rheumatoid factor; these tests are nonspecific and primarily help exclude alternative autoimmune disorders.[30] Antibodies directed against inner-ear or corneal antigens, and against heat shock proteins, may be present in approximately half of patients, but these are not standard diagnostic tests.[15][37]

Additional serologic testing may include antinuclear antibodies, antibodies to smooth muscle, lupus anticoagulants, cryoglobulins, anti-neutrophil cytoplasmic antibodies, or rheumatoid factor; these tests are nonspecific and primarily help exclude alternative autoimmune disorders.[30] Antibodies directed against inner-ear or corneal antigens, and against heat shock proteins, may be present in approximately half of patients, but these are not standard diagnostic tests.[15][37] Imaging is used primarily to evaluate systemic or vascular involvement. Magnetic resonance imaging (MRI) or computed tomography (CT) may identify cerebral ischemic changes or complications from vasculitis. Echocardiography, CT angiography, or MRI angiography can detect aortitis, aneurysms, or valvular abnormalities in patients with cardiovascular symptoms.[28][29] Overall, evaluation relies on a comprehensive history, detailed ophthalmologic and audiovestibular assessment, laboratory testing to exclude alternative diagnoses, and imaging to identify systemic involvement, given the absence of pathognomonic findings for Cogan syndrome.[1]

The primary goals of treatment in Cogan syndrome are to reduce the frequency and severity of disease flares; prevent irreversible SNHL, vestibular dysfunction, and ocular complications; and mitigate systemic manifestations, particularly vasculitis.[1] Corticosteroids are the first-line therapy. High-dose corticosteroids, such as intravenous methylprednisolone 500 mg to 1 g daily for 3 days (or oral prednisone ≥1 mg/kg/day), are used to control acute audiovestibular and ocular inflammation. Intratympanic steroid injections may be added to optimize hearing outcomes. Around 37% to 54% of patients with Cogan syndrome may experience persistent hearing loss despite corticosteroid therapy, necessitating escalation to immunosuppressive agents.[1] Immunosuppressive therapies are employed for refractory or progressive disease. Common agents include methotrexate, azathioprine, cyclophosphamide, cyclosporine A, JAK inhibitors, and rituximab. The choice of agent depends on disease severity, systemic involvement, and patient tolerance, as the rarity of Cogan syndrome limits the availability of randomized controlled trials. Therapy is typically reevaluated after 4 months, with discontinuation or adjustment if no improvement is observed.[1][39][40] Biologic therapies targeting tumor necrosis factor-α, particularly infliximab, have demonstrated efficacy in patients with resistant disease. A recent review reported clinical remission in 11 of 12 patients treated with infliximab.[41][42] Rituximab has also been shown to reduce systemic inflammation and preserve cochlear function, potentially avoiding cochlear implantation in severe cases.[43] Cochlear implantation is indicated for patients with severe or treatment-resistant sensorineural hearing loss. Early implantation is preferred to prevent intracochlear fibrosis or ossification, which can compromise outcomes. Post-implantation word recognition scores range from 82.5% to 94%, highlighting the effectiveness of timely surgical intervention.[44] Chronic vestibular dysfunction may be managed with benzodiazepines, antihistamines, or vestibular rehabilitation therapy, tailored to symptom severity.[45] Emerging therapies, including stem-cell-based approaches, are under investigation but require further study to establish long-term safety and efficacy.[46]

Cochlear implantation is indicated for patients with severe or treatment-resistant sensorineural hearing loss. Early implantation is preferred to prevent intracochlear fibrosis or ossification, which can compromise outcomes. Post-implantation word recognition scores range from 82.5% to 94%, highlighting the effectiveness of timely surgical intervention.[44] Chronic vestibular dysfunction may be managed with benzodiazepines, antihistamines, or vestibular rehabilitation therapy, tailored to symptom severity.[45] Emerging therapies, including stem-cell-based approaches, are under investigation but require further study to establish long-term safety and efficacy.[46] Ophthalmologic management involves topical corticosteroids combined with cycloplegics, administered as drops, gels, or ointments (eg, dexamethasone, prednisolone, fluorometholone, hydrocortisone). Treatment duration typically ranges from 6 to 12 months, with close monitoring for steroid-induced glaucoma or cataract formation. Approximately 90% of patients respond favorably, with blindness occurring in 5.5% to 12.7% of cases.[1][40] Systemic vasculitis, particularly involving large vessels, may require oral cyclophosphamide (2–3 mg/kg/day for 4–6 months) or cyclosporine (≤4 mg/kg/day) if the disease is unresponsive to initial therapy. Surgical intervention for ascending aorta aneurysms or aortic valve disease should generally be deferred until active inflammation is controlled to minimize perioperative risk.[29][40] In all cases, patient education is critical, emphasizing adherence to medical therapy, monitoring for complications, and timely evaluation of auditory, ocular, or systemic changes to optimize outcomes and prevent irreversible organ damage.[1]

Diagnosing Cogan syndrome is challenging due to its overlap with other audiovestibular, ophthalmologic, and systemic autoimmune disorders. As a diagnosis of exclusion, careful evaluation to rule out conditions with similar ocular and audiovestibular features is essential. Susac syndrome (retinocochleocerebral vasculopathy): SICRET (small infarcts of cochlear, retinal, and encephalic tissues) syndrome is characterized by microvascular occlusions affecting the cochlea, retina, and brain, leading to sensorineural hearing loss, visual disturbances, and neurologic deficits. Unlike Cogan syndrome, lesions are primarily arteriolar, and ocular involvement manifests as branch retinal artery occlusions.[3] Congenital syphilis: Interstitial keratitis, sensorineural hearing loss, and Hutchinson teeth (Hutchinson triad) may mimic Cogan syndrome. Serologic testing for syphilis is essential to exclude this diagnosis.[47] Vogt-Koyanagi-Harada syndrome: Features of this syndrome include uveitis, sensorineural hearing loss, meningismus, poliosis, and alopecia. Although ocular and auditory findings overlap with Cogan syndrome, the presence of skin depigmentation and alopecia distinguishes this syndrome from Cogan syndrome.[38][48] Granulomatosis with polyangiitis: This syndrome is a small-vessel vasculitis that typically involves the ear, eye, respiratory tract, and kidneys. Detection of cytoplasmic anti–neutrophil cytoplasmic antibodies (proteinase 3 antibodies) and characteristic pulmonary and renal involvement can help differentiate granulomatosis with polyangiitis from Cogan syndrome, which does not consistently exhibit these findings. Polyarteritis nodosa and Takayasu arteritis: Large- and medium-vessel vasculitides may present with systemic features, including fever, weight loss, myalgias, and aortic involvement. Imaging and serology are critical to distinguish these from Cogan syndrome–associated vasculitides.[17]

Granulomatosis with polyangiitis: This syndrome is a small-vessel vasculitis that typically involves the ear, eye, respiratory tract, and kidneys. Detection of cytoplasmic anti–neutrophil cytoplasmic antibodies (proteinase 3 antibodies) and characteristic pulmonary and renal involvement can help differentiate granulomatosis with polyangiitis from Cogan syndrome, which does not consistently exhibit these findings. Polyarteritis nodosa and Takayasu arteritis: Large- and medium-vessel vasculitides may present with systemic features, including fever, weight loss, myalgias, and aortic involvement. Imaging and serology are critical to distinguish these from Cogan syndrome–associated vasculitides.[17] Interstitial keratitis from infectious or autoimmune causes: In addition to syndromic conditions considered in the differential for Cogan syndrome, the differential diagnosis of interstitial keratitis includes infectious etiologies—such as syphilis, chlamydia, leprosy, tuberculosis, brucellosis, leptospirosis, Lyme disease, herpes viruses, measles, mumps, pox viruses, and parasitic infections (eg, onchocerciasis)—as well as autoimmune diseases, including rheumatoid arthritis, sarcoidosis, and granulomatosis with polyangiitis, which may mimic the ocular manifestations of Cogan syndrome.[1][49][1][50][51][52]

The prognosis of Cogan syndrome is highly variable and largely depends on the subtype, the severity of systemic involvement, and the timeliness of intervention. Typical Cogan syndrome generally carries a more favorable prognosis given its relatively limited systemic involvement when compared to atypical Cogan syndrome. In both variants, ophthalmologic symptoms resolve in approximately 90% of patients with treatment, and the prevalence of blindness is around 5.5% to 12.7%.[1] Auditory outcomes are less favorable than ophthalmologic outcomes. Long-term sensorineural hearing loss may progress to deafness despite corticosteroid or immunosuppressive therapy. In a cohort of 60 patients treated at the Mayo Clinic from 1940 to 2002, complete hearing loss occurred in 1 ear in 18% of patients and in both ears in 52%. Cochlear implantation remains an effective rescue intervention for those with profound hearing loss.[44] Cardiovascular involvement, though rare, represents the leading cause of mortality in Cogan syndrome. Large-vessel vasculitis may manifest as aortitis, aortic aneurysm or dissection, aortic valve perforation, or coronary artery disease, potentially leading to myocardial infarction or sudden death.[28] Neurologic complications occur in up to 33% of patients, including headache, hemiparesis, hemiplegia, aphasia, cerebellar syndrome, epilepsy, meningeal syndrome, or encephalitis. These manifestations typically result from inflammatory involvement of medium- and large-sized vessels supplying the central nervous system, and the effects may be long-term or permanent.[1][22]

Cogan syndrome can be complicated by permanent sensorineural hearing loss (50%), blindness (5.5%–12.7%), or complications related to systemic vasculitis.[1] Systemic vasculitis has been reported in 15% to 21% of cases and typically involves large- or medium-sized vessels, although vessels of any size may be affected.[53] Life-threatening cardiovascular complications were reported in 10% of cases, including aortic insufficiency, aneurysms, and dissections.[54] Other valves may also be involved, leading to complications such as mitral insufficiency.[55] Other organs that may be affected by systemic vasculitis in Cogan syndrome include the kidneys and brain.[36] Cerebrovascular ischemia, including lacunar infarcts and transient ischemic attacks, may result in neurological complications, including aphasia, hemiplegia, and hemiparesis.[56]

Cogan syndrome is a rare autoimmune disorder that presents with audiovestibular and ophthalmologic symptoms, classically nonsyphilitic interstitial keratitis. Because of the disorder's rarity and nonspecific clinical features, which necessitate a diagnosis of exclusion, prompt recognition and treatment are challenging and require strong communication and trust among clinicians, patients, and caregivers. Insufficient treatment or treatment resistance may result in permanent deafness or blindness. The first line treatment for Cogan syndrome is corticosteroids, though multiple immunosuppressive drugs have been used for more aggressive cases.[29] Cochlear implantation is a surgical option for patients with severe sensorineural hearing loss for whom intensive immunosuppressive regimens are not successful.[29] Patients and caregivers should be educated about the prognosis, management, and expected outcomes of Cogan syndrome to support shared decision-making and optimize clinical outcomes.

Collaboration among the entire healthcare team is mandatory for the management of Cogan syndrome. Primary care clinicians should be educated about this disorder, especially if patients present with progressive hearing loss and eye pain. Referrals to ophthalmology, otolaryngology, neurology, and cardiology are often necessary, particularly in cases of systemic involvement. Screening for other autoimmune diseases, in consultation with rheumatology, should also be considered to improve prognosis and outcomes. The views expressed in this abstract/manuscript are those of the author(s) and do not reflect the official policy or position of the Department of the Army, Department of Defense, or the United States Government.